TrialClinical lymphoma, myeloma & leukemia2015

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

Naveen Pemmaraju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.